NSE: BIOCON | BSE: 532523

Slowing Down Stock

Download real time

316.55 10.25 (3.35%)

3.3M NSE+BSE Volume

NSE 11 Apr, 2025 3:31 PM (IST)

38,005

Market Cap

Market Leader

1.2

Beta 1Year

Very High Volatility

US FDA Approval

Biocon receives USFDA approval for Jobevne, used in cancer treatment, with a market size of ~$2 bn See details

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Search Inside the pdf :

Biocon Ltd.

01 Feb 2025

316.55

3.35%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock with a target price of Rs 405/share, implying a 12% upside potential from CMP

Biocon Ltd. is trading below all available SMAs

Biocon Ltd.

13 Jan 2025, 12:00AM

316.55

3.35%

‘VAI’ status for Malaysian site provides regulatory boost

Buy: Biocon Ltd.

Recommendation Target

Motilal Oswal

Biocon (BIOS) has received ‘Voluntary Action Indicated’ (VAI) status for its Malaysian site. With this, BIOS now has all critical sites for biosimilars under USFDA compliance, improving its business prospects in the US market.

Biocon Ltd. is trading below all available SMAs

Biocon Ltd.

20 Nov 2024

316.55

3.35%

BIOCON LTD

Accumulate: Biocon Ltd.

Target

Geojit BNP Paribas

Biocon Ltd. is trading below all available SMAs

Biocon Ltd.

12 Nov 2024, 12:00AM

316.55

3.35%

Soft quarter, expect recovery in H2

Buy: Biocon Ltd.

Sharekhan

Revenues stood at Rs. 3,590 crore, up 4% y-o-y and a 5% rise q-o-q. EBITDA reached Rs. 730 crore, down 1% y-o-y but up 24% q-o-q. PAT stood at Rs. 27 crore, a decline of 84% y-o-y and 97% q-o-q.

Biocon Ltd. is trading below all available SMAs

Biocon Ltd.

31 Oct 2024

316.55

3.35%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock.

Biocon Ltd. has an average target of 402.75 from 4 brokers.

Biocon Ltd.

09 Aug 2024

316.55

3.35%

Result Update:Biocon

Buy: Biocon Ltd.

Axis Direct

We have BUY on the stock

Biocon Ltd. is trading below all available SMAs

Biocon Ltd.

05 Aug 2024

316.55

3.35%

Pick of the Week:05 AUGUST 2024

Buy: Biocon Ltd.

Target

Axis Direct

We recommend BUY With TP OF RS 390 which implies an upside of 10% from the current market price (CMP).

Biocon Ltd. is trading below all available SMAs

Biocon Ltd.

28 Jun 2024

316.55

3.35%

GLP product launch a big opportunity

Buy: Biocon Ltd.

Target

Sharekhan

Biocon recently signed an exclusive licensing and supply agreement with Handok, a South Korean specialty pharma company for commercialization of synthetic liraglutide.

Biocon Ltd. is trading below all available SMAs

Biocon Ltd.

17 May 2024

316.55

3.35%

Result Update:Biocon

Buy: Biocon Ltd.

Recommendation Target

Axis Direct

We have BUY on the stock

Biocon Ltd. is trading below all available SMAs

Biocon Ltd.

12 Feb 2024, 12:00AM

316.55

3.35%

Result Update:Biocon

Hold: Biocon Ltd.

Target

Axis Direct

The company's capital allocation is on two fronts - R&D and the acquisition of Viatris.This has resulted in returns ratios falling below ~10% despite growth in the business. A huge looming net debt of $1.2 Bn could lead to further stake dilution in Biocon biologics. Recommendation: HOLD

Biocon Ltd. is trading below all available SMAs

Is Biocon Ltd. worth buying?

714 Votes:

Buy 75.07%

Sell 16.39%

Hold 8.54%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf